4DMedical有限公司（股票代码：4DX.AU）今日盘中大涨5.38%，引起了市场的关注。
消息面上，公司宣布启动一项明确的临床证据计划，该计划旨在为其Ct:Vq™技术加速进入急性肺栓塞（PE）市场铺平道路，这被视为一项积极的业务进展，增强了投资者对公司未来增长潜力的信心。
该临床证据计划的核心目标是通过生成坚实的临床数据，来支持这项创新技术在关键医疗领域的应用与采纳，市场预期此举将有助于公司拓展新的市场机会。
4DMedical有限公司（股票代码：4DX.AU）今日盘中大涨5.38%，引起了市场的关注。
消息面上，公司宣布启动一项明确的临床证据计划，该计划旨在为其Ct:Vq™技术加速进入急性肺栓塞（PE）市场铺平道路，这被视为一项积极的业务进展，增强了投资者对公司未来增长潜力的信心。
该临床证据计划的核心目标是通过生成坚实的临床数据，来支持这项创新技术在关键医疗领域的应用与采纳，市场预期此举将有助于公司拓展新的市场机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.